BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.

Calamos Advisors LLC reduced its position in shares of Boston Scientific Corporation (NYSE: BSX) by 21.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 894,430 shares of the medical equipment provider's stock after selling 244,349

Calamos Wealth Management LLC boosted its stake in Boston Scientific Corporation (NYSE: BSX) by 52.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 155,038 shares of the medical equipment provider's stock after buying an additional 53,252 shares during the period. Calamos Wealth

Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.

Sowell Financial Services LLC cut its position in Boston Scientific Corporation (NYSE: BSX) by 51.1% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,546 shares of the medical equipment provider's stock after selling 28,806 shares during the quarter. Sowell Financial Services

Boston Scientific is recommended as a buy with a $109 target price, implying 14% upside, driven by robust demand and niche leadership. BSX outpaces market growth through focused M&A, strong execution in Cardiovascular and MedSurg segments, and sustained double-digit revenue and EPS expansion. Recent Q3 results exceeded expectations, prompting management to raise FY25 guidance; high demand for Watchman and FARAPULSE are key growth drivers.

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

BSX's Endoscopy unit targets an $8B market, spanning pancreaticobiliary, surgery and obesity, with plans to outgrow the market.

This basket of 64 medical device stocks could raise its dividend for decades.

Exchange Traded Concepts LLC increased its holdings in shares of Boston Scientific Corporation (NYSE: BSX) by 54.4% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,663 shares of the medical equipment provider's stock after buying an additional 22,791